Gene Therapy for Duchenne Muscular Dystrophy
Sector
Biotechnology
Company
Mid-Sized Biotech
Therapeutic Area
Rare Disease
Treatment Modality
Gene Therapy
Product Stage
Pre-Launch
Expertise
Medical
A leading biotech advanced gene therapies for Duchenne muscular dystrophy (DMD), seeking to redefine outcomes in a disease with few effective options. The program carried high expectations but also scrutiny from regulators, clinicians, payers, and advocacy groups given the complexities of trial design, durability of effect, and patient safety. The communications challenge was to establish scientific credibility while aligning clinical, regulatory, and economic narratives to support both launch and access.
Situation
A leading biotech advanced gene therapies for Duchenne muscular dystrophy (DMD), seeking to redefine outcomes in a disease with few effective options. The program carried high expectations but also scrutiny from regulators, clinicians, payers, and advocacy groups given the complexities of trial design, durability of effect, and patient safety. The communications challenge was to establish scientific credibility while aligning clinical, regulatory, and economic narratives to support both launch and access.
Situation
Approach
Our work centered on building a transparent, evidence-driven scientific narrative that explained mechanism, clarified trial design, and contextualized efficacy and safety outcomes. In parallel, we translated those same data into value-focused communications that supported payer and HTA discussions. This included creating a global publications plan spanning biomarker and functional outcomes, congress activities that elevated dialogue with neuromuscular KOLs, and field enablement materials that helped MSLs and market access teams anticipate payer questions. By linking clinical evidence with health-economic framing, we ensured consistency between the scientific and access stories.
Approach
Results
This integrated approach positioned the gene therapy as both pioneering and credible. By anchoring communications in transparent data while extending the narrative into value, cost-effectiveness, and long-term outcomes, the company reinforced confidence across clinicians, regulators, and payers. The result was stronger alignment among stakeholders and a clearer path to demonstrating not only scientific leadership but also justifiable value in one of the most closely watched rare disease markets.
Situation
A leading biotech advanced gene therapies for Duchenne muscular dystrophy (DMD), seeking to redefine outcomes in a disease with few effective options. The program carried high expectations but also scrutiny from regulators, clinicians, payers, and advocacy groups given the complexities of trial design, durability of effect, and patient safety. The communications challenge was to establish scientific credibility while aligning clinical, regulatory, and economic narratives to support both launch and access.
Approach
Our work centered on building a transparent, evidence-driven scientific narrative that explained mechanism, clarified trial design, and contextualized efficacy and safety outcomes. In parallel, we translated those same data into value-focused communications that supported payer and HTA discussions. This included creating a global publications plan spanning biomarker and functional outcomes, congress activities that elevated dialogue with neuromuscular KOLs, and field enablement materials that helped MSLs and market access teams anticipate payer questions. By linking clinical evidence with health-economic framing, we ensured consistency between the scientific and access stories.
Results
This integrated approach positioned the gene therapy as both pioneering and credible. By anchoring communications in transparent data while extending the narrative into value, cost-effectiveness, and long-term outcomes, the company reinforced confidence across clinicians, regulators, and payers. The result was stronger alignment among stakeholders and a clearer path to demonstrating not only scientific leadership but also justifiable value in one of the most closely watched rare disease markets.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Work With Us
Advance biology to belief—
sharper, faster, and leaner.
Connect with our Biography team to start a conversation.
Work With Us
Advance biology to belief—
sharper, faster, and leaner.
Connect with our Biography team to start a conversation.
Work With Us
Advance biology to belief—sharper, faster, and leaner.
Connect with our Biography team to start a conversation.